A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone
Blood (2023) 142 (Supplement 1): 4753.
Currently there are no citedby results. Try again later.
